Evercore ISI Group Initiates Coverage On Cardlytics with In-Line Rating, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has initiated coverage on Cardlytics (NASDAQ:CDLX) with an In-Line rating and set a price target of $4.
October 11, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Evercore ISI Group has initiated coverage on Cardlytics with an In-Line rating and a price target of $4, suggesting a neutral outlook.
The In-Line rating indicates that the analyst expects the stock to perform in line with the market. The price target of $4 suggests that the stock is fairly valued at its current price, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100